incmga00012
Incmga00012 is a drug used to treat Advanced Solid Tumors, Bladder Cancer, Breast Cancer, and other conditions. Incmga00012 is being actively studied in 8 studies and prior, has been studied in 1.
| Top Sponsors | Top Sites | Top Investigators |
|---|---|---|
| Incyte Corporation | Md Anderson Cancer Center | Sook Ryun Park |
| Asan Medical Center | Cedars-Sinai Medical Center | |
| BriaCell Therapeutics Corporation | Dana Farber Cancer Institute |
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
U
Recruiting
- Glioblastoma
- INCMGA00012
- +3 more
- Philadelphia, PennsylvaniaHospital of the University of Pennsylvania
2022-02-11
Feb 11, 2022B
Recruiting
- Breast Cancer Female
- Breast Neoplasm Female
- SV-BR-1-GM
- +4 more
- Santa Rosa, California
- +5 more
2022-03-10
Mar 10, 2022A
Not yet recruiting
- Esophageal Cancer
- INCMGA00012
- (no location specified)
2020-07-27
Jul 27, 2020M
Recruiting
- Well-differentiated/Dedifferentiated Liposarcoma
- INCMGA00012
- Palbociclib
- Basking Ridge, New Jersey
- +6 more
2021-12-21
Dec 21, 2021I
Not yet recruiting
- Retroperitoneal Sarcoma
- Resectable Sarcoma
- Doxorubicin
- +2 more
- Bordeaux, France
- +3 more
2022-03-04
Mar 4, 2022P
Recruiting
- Cancer of the Head and Neck
- INCAGN01876
- +2 more
- Portland, OregonPortland Providence Medical Center
2021-09-01
Sep 1, 2021I
Recruiting
- Advanced Solid Tumors
- INCB081776
- INCMGA00012
- New Haven, Connecticut
- +20 more
2022-04-06
Apr 6, 2022I
Recruiting
- Ovarian Cancer
- +10 more
- INCB106385
- INCMGA00012
- West Hollywood, California
- +26 more
2022-04-06
Apr 6, 2022I
